Christopher Pierce, MBA, serves as Vice President of Commercial. Previously Mr. Pierce worked at Pfizer Oncology from 2007 to 2017 in roles of increasing commercial responsibility, including the launch or in-line management of various oncology therapeutics such as Xalkori (crizotinib), Sutent (sunitinib), Inlyta (axitinib), Bosulif (bosutinib), Mylotarg (gemtuzumab ozagamicin), and Besponsa (inotuzumab ozogamicin). From 2004 to 2006, Mr Pierce worked at Millenium Pharmaceuticals managing market analytics for Velcade (bortezomib). Before Millenium, Mr. Pierce was a life sciences management strategy consultant. Mr. Pierce received his A.B. degree in biochemical sciences from Harvard College, graduating magna cum laude. He received his MBA from the Harvard Business School with high distinction, where he was named a George F. Baker scholar.